Who are ephedrine and phenylephrine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): labetalol intravenous, Experimental dosing of labetalol, Epinephrine Injection, Labetalol, Nifedipine, nebulized epinephrine, Norepinephrine intra-arteriel/hepatic.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ephedrine-and-phenylephrine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ephedrine and phenylephrine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ephedrine and phenylephrine (ephedrine and phenylephrine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic amine / Adrenergic agonist. Area: Cardiovascular / Respiratory.

marketed Sympathomimetic amine / Adrenergic agonist Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, beta-2 adrenergic receptor Cardiovascular / Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

ephedrine and phenylephrine (ephedrine and phenylephrine) — University Hospital, Clermont-Ferrand. Ephedrine and phenylephrine are sympathomimetic agents that stimulate alpha and beta adrenergic receptors to increase blood pressure and improve nasal/airway congestion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ephedrine and phenylephrine TARGET	ephedrine and phenylephrine	University Hospital, Clermont-Ferrand	marketed	Sympathomimetic amine / Adrenergic agonist	Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, beta-2 adrenergic receptor
labetalol intravenous	labetalol intravenous	Haseki Training and Research Hospital	marketed	Alpha-beta adrenergic antagonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Experimental dosing of labetalol	Experimental dosing of labetalol	Albany Medical College	marketed	Alpha-beta adrenergic antagonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Epinephrine Injection	Epinephrine Injection	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	marketed	Catecholamine; alpha and beta adrenergic agonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Labetalol, Nifedipine	Labetalol, Nifedipine	Medical College of Wisconsin	phase 3	Combination antihypertensive (beta-blocker + calcium channel blocker)	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, L-type calcium channel
nebulized epinephrine	nebulized epinephrine	Oman Medical Speciality Board	marketed	Sympathomimetic amine / Adrenergic agonist	Alpha-1 and beta-2 adrenergic receptors
Norepinephrine intra-arteriel/hepatic	Norepinephrine intra-arteriel/hepatic	University Health Network, Toronto	marketed	Sympathomimetic amine / Adrenergic agonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic amine / Adrenergic agonist class)

Al-Azhar University · 1 drug in this class
Amphastar Pharmaceuticals, Inc. · 1 drug in this class
Oman Medical Speciality Board · 1 drug in this class
University Health Network, Toronto · 1 drug in this class
University Hospital, Clermont-Ferrand · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ephedrine and phenylephrine — Competitive Intelligence Brief. https://druglandscape.com/ci/ephedrine-and-phenylephrine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing